For those long-term holders - my humble suggestion: ignore the...

For those long-term holders - my humble suggestion: ignore the short term gyrations in the price and the day-trade banter of failed expectations in share price.

Look at the big picture: Every announcement to date regarding PAT- DX-1, keeps confirming the potential of this novel antibody for the treatment of aggressive cancers in the DDR space: as a single agent or conjugated to nanoparticles or in combination therapy. Indeed the potential for PAT DX-1 is huge and should be viewed as game-changing platform DDR therapy in the most broadest sense.

For those who have held the stock since this time last year - the price has steadily climbed from less than 0.5c to around the 5c mark.

Moreover, the major shareholders (Calder and Stork) and now Maquarie and Mason-Stevens continue to increase their holdings.

We should be taking our cues from the major shareholders and the PAT DX-1 announcements to date "as a whole", not from the short-term disappointments (quite often bordering on the neurotic) of the the day-traders.